HYBRID EVENT: You can participate in person at Boston, Massachusetts, USA or Virtually from your home or work.
Speaker at World Obesity and Weight Management Congress 2026 - Hassan Massoud Heshmati
Keynote Presentation (In-person)
Hassan Massoud Heshmati, Endocrinology Metabolism Consulting, LLC, Hassan Heshmati and Valerie Shaw Endocrine Research, United States

Will be Updated Soon...

Speaker at World Obesity and Weight Management Congress 2026 - Melinda J Watman
Oral Presentation (In-person)
Melinda J Watman , President & Founder of Weighty Decision, United States

The majority of people with eating disorders (ED) are of higher-weight yet EDs are minimized, underreported and often go untreated in these individuals. These individuals are half as likely to receive a clinical diagnosis of an eating disorder from a health care practitioner as t [....] » Read More

Speaker at World Obesity and Weight Management Congress 2026 - Jesse Cochrane
Poster Presentation (In-person)
Jesse Cochrane, Lipedema Foundation, United States

Lipedema is a chronic condition characterized by disproportionate fat accumulation, inflammation, and pain, predominantly affecting women. Traditional treatments focus on symptom management, but emerging therapies, such as GLP-1/GIP receptor agonists like semaglutide and tirzepat [....] » Read More

Speaker at World Obesity and Weight Management Congress 2026 -  Aminata Mbaye
Poster Presentation (In-person)
Aminata Mbaye, UCAD, Senegal

The WHO defines obesity as an abnormal or excessive accumulation of body fat that may impair health. Obesity should be suspected when weight increases more rapidly than height; weight-for-height charts are the clinician’s primary tool. The WHO defines overweight as a BMI ab [....] » Read More

Speaker at World Obesity and Weight Management Congress 2026 - Marco Medeot
Poster Presentation (Virtual)
Marco Medeot, Ketogenic Research Hub, Italy

Introduction: GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide have demonstrated significant efficacy in weight reduction and metabolic improvement. However, emerging data suggest that up to 45% of weight loss with semaglutide may derive from fat-free [....] » Read More

Twitter XTwitter
Watsapp